A seminar in New Delhi commemorated Acharya Prafulla Chandra Ray's birth anniversary, focusing on his significant contributions to pharmaceutical sciences and his vision for indigenous research and self-reliance. Organised by DPSRU and VIBHA, the event highlighted Ray's pioneering efforts in "Swadeshi science" and his role in establishing India's pharmaceutical industry.
Bank credit to industry in India surged by 20 per cent year-on-year in July, significantly accelerating from the previous year, driven by strong expansion in sectors like engineering, gems and jewellery, and petroleum-related industries, according to the Reserve Bank of India (RBI). However, growth in gold loans, while still expanding, saw a sharp moderation.
Sun Pharmaceutical Industries reported a 27 per cent year-on-year increase in consolidated net profit to 2,894.7 crore for Q1FY27, with revenue growing 10 per cent to 15,299.8 crore, driven by strong performance in India and innovative medicines.
Sun Pharmaceutical Industries Ltd has announced its acquisition of US-based Organon & Co in an all-cash deal valued at an enterprise valuation of USD 11.75 billion, aiming to become a top 25 global pharmaceutical company.
One of the important topics of discussion between the two leaders is expected to be the Northern Sea Route and the Chennai-Vladivostok Maritime Corridor.
Researchers at IIT Madras have patented a chemical-free antibacterial surface that physically eliminates harmful bacteria, including "superbugs," without relying on antibiotics or disinfectants. This innovative technology uses specially engineered nanostructures to rupture bacterial cell walls, offering a sustainable solution to Antimicrobial Resistance (AMR) for biomedical and public health applications.
The political confidence required to place high-end Japanese aircraft and personnel on Indian soil is itself a data point.
It indicates a level of trust that would have been difficult to imagine when India-Japan defence ties were largely symbolic, explains Varun Arya.
rediffGURU Nayagam PP advises young aspirants how to pick the right course and career.
The benchmark BSE Sensex rebounded by 362 points, ending a four-day losing streak, driven by strong buying in metal, private banking, and oil and gas shares, while the broader NSE Nifty saw modest gains despite paring some advances in the closing session.
India has attracted foreign direct investment (FDI) worth approximately 4,896 crore across 29 projects since May, following the government's relaxation of norms under Press Note 2 of 2026. The revised rules permit investment without government approval from entities with up to 10 per cent non-controlling ownership by land-bordering countries.
Newly listed companies Vedanta Aluminium Metal, SBI Funds Management and Manipal Health Enterprises have entered the Rs 1 trillion mcap list since March 2026.
The question for the next 20 years is not whether India can become a $5 trillion or $10 trillion economy. Those are attractive targets, but the real question is whether India can create enough productive jobs, educate its children properly, make its cities liveable, and give hundreds of millions of people a substantially better life, asserts Ramesh Menon.
Rockwell Automation's CEO Blake Moret highlights India as the centrepiece of the company's Asian growth strategy, detailing its four-decade presence, significant employee base, and support for the 'Make in India' initiative. The company sees major opportunities in pharmaceuticals, automotive, food and beverage, and consumer products, with AI playing a crucial role in simplifying industrial automation and boosting productivity for Indian manufacturers, including MSMEs.
Indian pharmaceutical companies are not rushing to relocate manufacturing to the United States despite former President Donald Trump's renewed threat of tariffs up to 200 per cent on imported generic drugs. Instead, they are leveraging existing US plants, contract manufacturers, and making selective investments in complex products while maintaining India as their primary production hub.
'While salary increments are moderating compared to last year, not all functions are moving at the same pace.'
Companies are investing heavily in complex injectables, respiratory therapies and biosimilars to improve margins and diversify portfolios.
Indian companies' overseas expansion plans are holding strong despite geopolitical tensions in West Asia, driven by structural factors like supply-chain diversification, free trade agreements, and market expansion, according to Ajay Sharma, managing director and head of banking at HSBC India.
Russia remains India's biggest fertiliser supplier, with imports rising nearly 40 per cent in 2025.
For India, the goal is not simply to host another grand diplomatic gathering. It is to prove that a diverse coalition of emerging powers can still deliver.
'While higher prices may create some financial burden for patients and caregivers in the short term, uninterrupted access to treatment remains the greater priority.'
Sun Pharmaceutical Industries' acquisition of US-based Organon & Co. for $11.75 billion, the largest overseas acquisition by an Indian pharma company, has been met with mixed reactions from brokerages, who see strategic entry into women's health and biosimilars but also flag potential integration challenges and debt concerns.
The Indian banking sector is projected to experience a steady 9-13 per cent industrial credit growth in the first half of 2026, driven by capital expenditure, infrastructure development, and sectoral demand recovery, according to a Ficci-IBA survey.
A Parliamentary Standing Committee on Commerce has urged the Indian government to swiftly conclude the proposed India-US Bilateral Trade Agreement (BTA), while ensuring India's interests are protected, recommending complete exemption for key export products like generic medicines and smartphones from future US tariff increases.
Researchers at Delhi's Indraprastha Institute of Information Technology have developed 'MutAIverse', a generative AI platform designed to decode DNA damage and identify potential causes of cancer. Tested on head and neck cancer patients in Guwahati, the platform successfully traced exposure to smokeless tobacco as a contributing factor. This innovation aims to shift focus from just diagnosis to understanding causative factors, potentially aiding in prevention and protection.
India's pharmaceutical industry is experiencing increased bulk drug prices, particularly for APIs from China, following the escalation of the West Asia crisis in March. While current inventories provide a temporary buffer, concerns are mounting over the availability of key solvents and feedstocks, potentially leading to manufacturing disruptions and shortages in specific drug categories.
Indian benchmark stock indices Sensex and Nifty rebounded nearly 1 per cent, snapping a three-day decline, driven by rallies in Reliance Industries and Sun Pharma, alongside positive global market trends and easing geopolitical tensions.
Indian pharmaceutical companies are strategically increasing investments in the US market, focusing on specialty drugs, complex generics, respiratory products, and local manufacturing, despite a nearly 10 per cent fall in exports to the US in FY26 due to pricing pressure and competition in traditional generics.
BikeWo Green Tech and Kwik Flite Support have signed an initial pact to develop an integrated air cargo, aviation logistics, and multimodal freight platform. This collaboration aims to combine road mobility with aviation capabilities to serve various industries, focusing on high-value and time-sensitive logistics across India, including Tier-II and Tier-III cities.
Specialty chemicals maker Anupam Rasayan India Ltd has become the first company globally to commercialise Ethyl trifluoroacetate (ETFA) production using its proprietary continuous flow chemistry platform. This innovative technology offers significant advantages over traditional methods, and ETFA is a crucial component for pharmaceuticals, life sciences, and performance materials, with a global market estimated at USD 500-600 million.
Corporate India is projected to offer salary increments ranging from 8.6 per cent to 10.2 per cent across various industries in the financial year 2026-27, primarily fuelled by a sustained demand for skilled and execution-focused talent, according to a TeamLease Services report.
Sun Pharmaceutical Industries reported strong consolidated numbers for Q4 FY26, with net profit rising 26 per cent year-on-year to 2,714 crore, despite continued weakness in its US generics business. Growth in innovative medicines and increased R&D investments are helping to offset these pressures.
The remarkable rise of smallcaps reflects the emergence of a broad set of specialised businesses operating in industries where the sectoral tailwinds remain considerably stronger than macroeconomic headwinds, points out Debashis Basu.
Indian foreign direct investment (FDI) in the United States has reached approximately USD 16.4 billion, supporting around 70,800 jobs and contributing significantly to research and development, according to US Deputy Undersecretary Brandon Remington.
'The market is currently neither cheap enough to be exciting about nor expensive enough to worry about.'
The move follows reports from several state drug-regulatory authorities indicating misuse and hoarding oral formulations with high ethyl-alcohol concentration, which people use as a substitute for liquor.
Beijing clearly intends to extend the China-Myanmar Economic Corridor to Bangladesh as part of its larger Maritime Belt and Road Initiative to boost its Indian Ocean presence.
Bharti Airtel added 7.64 trillion in value over the past five years, making it the biggest wealth creator in India's private sector, while the IT sector, including TCS, Infosys, and Wipro, collectively lost 8.5 trillion in value, according to the latest Burgundy Private Hurun India 500 report.
Indian Pharmaceutical Alliance (IPA) on Friday said US President Donald Trump's move to impose 100 per cent import tariffs on pharmaceutical drugs from October 1 will impact only patented and branded products, not generic medicines.
India's procurement of Venezuelan crude oil has picked up momentum since April and the South American nation has already emerged as the third largest oil supplier to the country.
Finance Minister Nirmala Sitharaman on Sunday proposed Rs 10,000 crore investment in the biopharma sector over the next five years, a move which would give a boost to the country's pharmaceuticals industry.
